Detection method and application of PBMC's immune system reconstruction ability
By calculating the proportion of CD45RA positive cells among CD3 positive cells in PBMC samples and defining the reconstruction index RI≥0.2, the problems of long time consumption and high cost of existing detection methods are solved, realizing rapid and accurate PBMC screening and the establishment of humanized models, which promotes the development of anti-tumor immunotherapy drugs.
Patent Information
- Application Number
- CN202110677007.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-06-18
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-06-18
AI Technical Summary
Existing methods for detecting immune system reconstitution capacity in PBMCs are time-consuming and costly, making Donor screening and experimental time planning difficult, hindering the rapid establishment of humanized experimental animal models, and affecting the development of anti-tumor immune-related drugs.
By calculating the proportion of CD45RA-positive cells among CD3-positive cells in PBMC samples, a reconstitution index (RI) was defined, and an RI ≥ 0.2 was set as a good reconstitution standard. The immune system reconstitution capacity of PBMCs was rapidly detected in vitro using flow cytometry, simplifying the Donor screening process.
This method enables rapid and accurate determination of PBMC reconstitution status in mice, reduces costs, improves the efficiency of donor selection and experimental time planning, promotes the rapid establishment of humanized experimental animal models, and supports the development of anti-tumor immune-related drugs.
Smart Images

Figure CN113588934B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a method for detecting the immune system reconstruction ability of PBMC and its application. Background Art
[0002] Experimental animal models play an important role in the development of medical life sciences. Rodent models are widely used in the research of drugs and vaccines, but due to species differences or the difference between the pathogens used and those that infect humans, many drugs or vaccines cannot effectively target human diseases and cannot be used clinically. Parasites, bacteria, and viral infections are the main pathogenic factors that endanger human health. The infection and pathogenicity characteristics of many pathogens are species-specific, such as HIV, which only infects human cells but not mouse cells. Due to the lack of ideal animal disease models, in-depth research on the mechanisms and prevention and treatment of corresponding diseases is limited. The establishment of humanized mouse models provides a new option for the study of human diseases. Immune system humanized mice refer to mice that have reconstructed the human immune system by transplanting human hematopoietic stem cells or immune tissues and cells.
[0003] In the current development of tumor immunotherapy drugs, there is an urgent need to construct an experimental animal model containing a human immune system. Among them, human PBMC is used as a representative model to reconstruct the human immune system in mice, which can be used well for the efficacy evaluation of immune checkpoint tumor immunotherapy drugs. However, the reconstruction ability of donors from different individual sources in the population varies greatly, so that each donor must be screened to obtain qualified PBMCs (peripheral blood mononuclear cells) for the next step of efficacy experiments. The brief steps are to use severely immunodeficient mice, inject a large dose of PBMCs (5×10E6 / mouse) into the tail vein, and after 2 to 4 weeks, evaluate the strength of a PBMC's reconstruction ability in mice, which is manifested as human CD45 positivity, a cell signal indicator of the human immune system.
[0004] However, this process of detecting and reconstructing capabilities is time-consuming and costly, which is not convenient for donor selection and experimental time planning, hinders the rapid establishment of humanized experimental animal models used in drug development, and is not conducive to the development of new anti-tumor immune-related drugs. Summary of the invention
[0005] Based on this, it is necessary to provide an accurate and rapid method for detecting the immune system reconstruction ability of PBMCs.
[0006] A method for detecting the immune system reconstruction ability of PBMCs comprises the following steps:
[0007] Obtain PBMC samples;
[0008] Obtaining a ratio a of CD3-positive cells in the PBMC sample and b ratio of CD45RA-positive cells in the CD3-positive cells, and calculating the ratio of CD45RA-positive cells in the PBMC sample by a×b as a reconstruction index;
[0009] The larger the reconstruction index value is, the higher the immune system reconstruction ability of the PBMC sample is, and the cut-off value of the reconstruction index is 0.2.
[0010] In one embodiment, the method for obtaining the ratio of CD45RA-positive cells in the CD3-positive cells comprises the following steps: obtaining the ratio c of CD45RO-positive cells in the CD3-positive cells, and calculating the ratio of CD45RA-positive cells in the CD3-positive cells by 1-c.
[0011] In one embodiment, the PBMC sample is a human PBMC sample, and the method for obtaining the proportion of CD3 positive cells in the PBMC sample comprises the following steps: obtaining the number d of CD45 positive cells and the number e of CD3 positive cells in the PBMC sample, and calculating the proportion of CD3 positive cells in the PBMC sample according to e / d.
[0012] In one embodiment, flow cytometry is used to detect the proportion of CD45RA positive cells in the PBMC sample.
[0013] In one embodiment, the flow cytometry comprises the following steps: taking a PBMC sample into a flow tube, staining it with a fluorescent antibody, and then placing it in a flow cytometer for detection and analysis.
[0014] In one embodiment, the method of staining with fluorescent antibodies comprises the following steps: mixing the PBMC sample with the fluorescent antibody, incubating at room temperature in the dark for 10 to 30 minutes, adding a buffer solution, centrifuging at 100 g to 400 g for 1 to 5 minutes to obtain a precipitate, and then adding a buffer solution to resuspend the precipitate.
[0015] In one embodiment, the reconstitution ability is the reconstitution ability reflected in a humanized immune system mouse model; preferably, the mice used in the model are T / B / NK cell combined-deficient mice.
[0016] The present invention also provides a method for screening drugs for treating immunodeficiency diseases, comprising the following steps:
[0017] The immune system reconstitution ability of PBMCs was detected according to the detection method described above;
[0018] PBMCs with a reconstruction index > 0.2 were selected and inoculated into experimental animals to construct experimental animal models;
[0019] Candidate drugs are tested using the experimental animal model.
[0020] The present invention also provides a computer-readable storage medium, which is used to store computer instructions, programs, code sets or instruction sets. When the computer-readable storage medium is run on a computer, the computer executes the detection method as described above.
[0021] The present invention also provides an electronic device, comprising:
[0022] one or more processors; and
[0023] A computer-readable storage medium is used to store computer instructions, programs, code sets or instruction sets, which, when executed on a computer, enable the one or more processors to implement the detection method as described above.
[0024] The traditional method for testing the immune system reconstruction capacity of PBMC can only be performed by injecting PBMC into mice, which inevitably leads to the following problems: (1) The economic cost of in vivo screening is high. The existing screening method must rely on high-level animal facilities that can raise severely immunodeficient mice. Each PBMC screening generally requires 3 to 5 severely immunodeficient mice, which is very costly. (2) The screening time is long. The reconstruction process of PBMC in animals takes 2 to 3 weeks, so it takes a long time to determine the reconstruction capacity of a donor. Therefore, determining the reconstruction capacity of PBMC in mice requires a lot of time and economic costs.
[0025] The present invention summarizes the experience of multiple screenings and defines the reconstruction index (RI) of each Donor. When the reconstruction index is greater than 0.2, it can be considered that the Donor is well reconstructed within 20 days, so that it can be separated from the mouse and accurately and quickly determine the reconstruction status of the Donor in the mouse in vitro. In this way, the selection of Donors and experimental time planning are greatly facilitated, while also reducing costs. It can quickly and well promote the establishment of humanized experimental animal models used in drug research and development, and help the development of new anti-tumor immune-related drugs. The detection method of the present invention quantifies the reconstruction ability of PBMC through the reconstruction index, does not rely on animal rooms, and only requires conventional equipment in tumor immunology laboratories, such as flow cytometers, etc., and can be completely operated in vitro. The detection method of the present invention requires extremely short time, for example, using flow cytometry, the results can be obtained within two hours. Moreover, if the PBMC supplier can provide the corresponding indicator data, the flow cytometry can be completely omitted, and only calculation is required to determine. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of the relationship between T cell proliferation ability and effector function;
[0027] Figure 2 to Figure 10 The flow cytometry detection results using CD3 fluorescent antibody and CD45RO fluorescent antibody staining in Examples 1 to 9 are respectively;
[0028] Figure 11-12 These are the flow cytometry detection results of Examples 10 to 11 using CD3 fluorescent antibody and CD45RA fluorescent antibody staining respectively;
[0029] Figures 13 to 19 The flow cytometry detection results of Examples 12 to 18 using CD3 fluorescent antibody, CD45RO fluorescent antibody and CD45RA fluorescent antibody staining respectively;
[0030] Fig. 20 is the reconstitution curve of PBMC in mice of Examples 1 to 9;
[0031] Fig.21 is the reconstitution curve of PBMC in mice of Examples 10 to 18;
[0032] Fig. 22 The linear correlation regression of the reconstruction index and the reconstruction ratio and the determination of the cut-off value in Example 20;
[0033] Figure 23 to Figure 34 The flow cytometry results of 12 PBMCs in Example 21;
[0034] Fig.35 This is the correlation between the reconstruction index and the reconstruction ratio of the 12 PBMCs in Example 21. DETAILED DESCRIPTION
[0035] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively below, and preferred embodiments of the present invention are provided. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0037] A method for detecting the immune system reconstruction ability of PBMCs according to an embodiment of the present invention comprises the following steps:
[0038] Obtain PBMC samples;
[0039] The proportion of CD3-positive cells in the PBMC sample, a, and the proportion of CD45RA-positive cells in the CD3-positive cells, b, were obtained, and the proportion of CD45RA-positive cells in the PBMC sample was calculated by a×b as the reconstruction index;
[0040] The larger the reconstruction index value, the higher the immune system reconstruction ability of the PBMC sample, and the cut-off value of the reconstruction index is 0.2.
[0041] In the development of new drugs for tumor immunity, especially the development of immune checkpoint drugs represented by PD1 antibody biomacromolecule drugs, a humanized immune system is needed to test the efficacy of biomacromolecule drugs. Mononuclear immune cells (PBMCs, the donors are called Donors) derived from human peripheral blood are injected into severe immunodeficient mice (T / B / NK cell co-deficiency) through the tail vein, which can simply and quickly construct humanized animal models and can be used for in vivo efficacy testing of most immune checkpoint drugs. However, the ability of PBMCs from healthy people to reconstruct in animals varies greatly, that is, some donors (Donors) can reconstruct well, while others are difficult to reconstruct. At present, PBMC reconstruction basically requires batch screening in animals to determine whether each Donor can reconstruct. The process of PBMC reconstruction in mice is actually the process of T cell expansion. After PBMCs enter the mouse body, they are quickly eliminated non-specifically by the mouse immune system, leaving only a part of human T cells. These residual T cells will gradually accumulate cytokines, especially IL2, to maintain T cell survival and support T cell expansion. After accumulating to a certain amount, the T cells will be cloned and expanded, and finally a considerable proportion of humanized T cells will be present, indicating that the humanized animal experimental model of the immune system is successfully established.
[0042] CD45RA+T (CD45RA positive T) is a cell population with strong T cell expansion and proliferation ability, that is, naive T cells, which have great proliferation potential. The corresponding CD45RO+T (CD45RO positive T) effector cells have strong effector functions but weak proliferation ability (such as Figure 1As shown). Further, the naive T of T cells was studied, and it was found that the reconstruction in mice had a clear positive correlation with the proportion of naive T (CD45RO negative, i.e. CD45RO-, equivalent to CD45RA positive, i.e. CD45RA+) subpopulations, and a significant negative correlation with the CD45RO+ memory T cell population. The present invention summarizes the experience of multiple screenings and defines the reconstruction index RI of each Donor. When the reconstruction index is greater than 0.2, it can be considered that the Donor is well reconstructed within 20 days, so that it can be separated from the mouse and the reconstruction status of the Donor in the mouse can be accurately and quickly determined in vitro. In this way, the selection of Donors and the experimental time planning are greatly facilitated, while also reducing costs. It can quickly and effectively promote the establishment of humanized experimental animal models used in drug research and development, and help the development of new anti-tumor immune-related drugs.
[0043] It can be understood that the cut-off value in medicine means the dividing value, critical value or cut-off value, which is the positive judgment value or "threshold value". That is to say, if the test value is greater than the cut-off value, it is positive, and if it is less than the cut-off value, it is negative. That is, if the reconstruction index is greater than 0.2, it can be considered that the donor will be well reconstructed within 20 days. The reconstruction index is used to determine the reconstruction ability of unknown donors. When it is greater than 0.2, it can be very clearly shown that the donor can reconstruct well, and when it is less than 0.2, the possibility of good reconstruction will be greatly reduced. Therefore, using RI as an indicator to evaluate the reconstruction ability of unknown donors is very simple, fast and convenient.
[0044] In a specific example, the method for obtaining the ratio of CD45RA-positive cells in CD3-positive cells includes the following steps: obtaining the ratio c of CD45RO-positive cells in CD3-positive cells, and calculating the ratio of CD45RA-positive cells in CD3-positive cells by 1-c. T cells can be divided into two relative groups according to CD45RO and CD45RA, so the ratio of CD45RA-positive cells in CD3-positive cells can be obtained by subtracting the ratio of CD45RO-positive cells in CD3-positive cells.
[0045] In a specific example, the PBMC sample is a human PBMC sample, and the method for obtaining the proportion of CD3-positive cells in the PBMC sample includes the following steps: obtaining the number d of CD45-positive cells and the number e of CD3-positive cells in the PBMC sample, and calculating the proportion of CD3-positive cells in the PBMC sample according to e / d. Human PBMCs are basically CD45-positive, so the number of CD45-positive cells is equivalent to the number of whole cells.
[0046] In a specific example, flow cytometry is used to detect the proportion of CD45RA positive cells in the PBMC sample. It is understood that the method for detecting cell types and proportions is not limited thereto and can be selected as needed.
[0047] In a specific example, flow cytometry includes the following steps: taking a PBMC sample into a flow tube, staining it with a fluorescent antibody, and then placing it in a flow cytometer for detection and analysis.
[0048] In a specific example, the method of staining with fluorescent antibodies includes the following steps: mixing the PBMC sample with the fluorescent antibody, incubating at room temperature in the dark for 10 to 30 minutes, adding a buffer, centrifuging at 100 g to 400 g for 1 to 5 minutes to obtain a precipitate, and then adding a buffer to resuspend.
[0049] In a specific example, the above-mentioned reconstruction ability is the reconstruction ability reflected in the humanized immune system mouse model. Preferably, the mice used in the above-mentioned model are T / B / NK cell combined deficiency mice.
[0050] A method for screening drugs for treating immunodeficiency diseases according to an embodiment of the present invention comprises the following steps:
[0051] The immune system reconstitution ability of PBMCs was detected according to the detection method described above;
[0052] PBMCs with a reconstruction index > 0.2 were selected and inoculated into experimental animals to construct experimental animal models;
[0053] Candidate drugs are tested using the experimental animal models described above.
[0054] In a specific example, the above-mentioned immunodeficiency disease is a tumor.
[0055] A computer-readable storage medium according to an embodiment of the present invention is used to store computer instructions, programs, code sets or instruction sets, which, when executed on a computer, enable the computer to execute the detection method described above.
[0056] An electronic device according to an embodiment of the present invention comprises: one or more processors; and a computer-readable storage medium for storing computer instructions, programs, code sets or instruction sets, which, when executed on a computer, enable the one or more processors to implement the detection method as described above.
[0057] The leukocyte differentiation antigen detection reagent of one embodiment of the present invention is used in detecting the immune system reconstruction ability of PBMC, and the above leukocyte differentiation antigen detection reagent includes CD45RA antibody. In a specific example, the leukocyte differentiation antigen detection reagent also includes one or more of CD3 antibody, CD45RO antibody and CD45 antibody.
[0058] The following are specific embodiments.
[0059] 1. Overall experimental process:
[0060] 1.1 Detect the proportion of CD3, CD45RA, and CD45RO cells using flow cytometry;
[0061] 1.2 Calculate the product of the proportion of CD3 of total cells and the proportion of CD45RA+ (or CD45RO-) of CD3 to obtain the reconstruction index RI.
[0062] 1.3 Donors with RI ≥ 0.3 are judged to have good reconstruction capabilities.
[0063] 2. Specific instruments, reagents and operations are as follows:
[0064] Table 1 Instrument information
[0065]
[0066]
[0067] Table 2 Reagent and consumables information
[0068] Reagent name brand Part Number 1640 Cell Culture Medium Thermo C11875500BT Fetal bovine serum BI 04-001-1A Trypsin-EDTA (0.25%) Gibco 25200056 PBS Gibco C20012500BT Anti-CD45RA eBioscience 11-0458-42 Anti-CD45RO eBioscience 12-0457-42 Anti-CD3 eBioscience 56-0038-42 PBMC Miao Shun /
[0069] 2.1 Cell recovery:
[0070] (1) Before thawing cells, wipe the clean bench with alcohol, irradiate with UV light for 15 minutes, turn on the centrifuge, and set the water bath to 37°C;
[0071] (2) Prepare complete culture medium: add 10% FBS and 1% penicillin-streptomycin to 1640 culture medium;
[0072] (3) Prepare 10 mL of complete culture medium for later use;
[0073] (4) Thawing cells: Take out the required cells from liquid nitrogen, check whether the cell number is correct, and quickly shake the cryotube in a water bath. After thawing, transfer to 10 mL of complete culture medium;
[0074] (5) Washing cells: Centrifuge at 300 g for 10 minutes and discard the supernatant;
[0075] (6) Resuspend the cells in PBS and count and adjust the concentration to 1×10E6 / mL for use in reconstitution of injected mice and flow cytometry to measure the reconstitution index (RI).
[0076] 2.2 Flow cytometry reconstruction index (RI) process:
[0077] (1) Sample acquisition: 100 μL of the above-mentioned spare cells were taken into three flow cytometry tubes, numbered 1#, 2#, and 3#;
[0078] (2) Cell staining:
[0079] Prepare sample test tubes: add 5 μL CD45RA, 5 μL CD45RO, and 5 μL CD3 antibody to tube 1, incubate at room temperature in the dark for 20 min, add 1 mL PBS, centrifuge at 300 g for 3 min, resuspend in 100 μL PBS and run flow cytometry;
[0080] Prepare CD45RA FMO control tube: add 5 μL CD45RA iso-type, 5 μL CD45RO, and 5 μL CD3 antibody to tube 2, incubate at room temperature in the dark for 20 min, add 1 mL PBS, centrifuge at 300 g for 3 min, resuspend in 100 μL PBS and run flow cytometry;
[0081] Prepare CD45RA FMO control tube: add 5 μL CD45RA, 5 μL CD45RO iso-type, and 5 μL CD3 antibody to tube 3, incubate at room temperature in dark for 20 min, add 1 mL PBS, centrifuge at 300 g for 3 min, resuspend in 100 μL PBS and run flow cytometry;
[0082] (3) Run the samples on a flow cytometer and collect CD3 gate cells with a number of ≥ 10,000 events;
[0083] (4) Results The professional flow cytometry software Flowjo or the analysis software that comes with the flow cytometry machine was used to analyze the proportion of CD3, CD45RA, and CD45RO cell populations.
[0084] (5) The reconstruction index is calculated based on the ratio. The reconstruction index (RI) is calculated as follows:
[0085] First determine the CD3 ratio (a), i.e. CD3 of total cells; and the CD45RA ratio (b), i.e. CD45RA ofCD3; and the CD45RO ratio (c), i.e. CD45RO of CD3. In the actual calculation process, the CD45RO of CD3 ratio is approximately equal to 1-(CD45RA of CD3), and vice versa. The reconstruction index RI = a×b, or RI = a×(1-c), RI>0.2 means that the Donor is considered to have reconstructed well within the specified time (2 weeks), and its significance level is set at α=0.05, and the confidence interval is 95%.
[0086] Example 1
[0087] Donor No. 11: PBMCs of Donor No. 11 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 2 shown.
[0088] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 56.777%, while the proportion of CD45RA to CD3 is 64.432%, RI = 56.777% × 64.432% = 0.365; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 35.519%, RI = 56.777% × (1-35.519%) = 0.366; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0089] Example 2
[0090] Donor No. 12: PBMCs of Donor No. 12 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 3 shown.
[0091] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 40.244%, while the proportion of CD45RA to CD3 is 70.216%, RI = 40.244% × 70.216% = 0.283; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 29.710%, RI = 40.244% × (1-29.710%) = 0.283; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0092] Example 3
[0093] Donor No. 13: PBMCs of Donor No. 13 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 4 shown.
[0094] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 57.539%, while the proportion of CD45RA to CD3 is 62.016%, RI = 57.539% × 62.016% = 0.357; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 37.915%, RI = 57.539% × (1-37.915%) = 0.357; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0095] Example 4
[0096] Donor No. 14: PBMCs of Donor No. 14 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 5 shown.
[0097] The reconstruction index RI value is calculated as follows: CD3 accounts for 53.365% of the total cell number, while CD45RA accounts for 69.857% of CD3, RI = 53.365% × 69.857% = 0.373; or the CD45RO ratio is calculated, CD45RO accounts for 30.064% of CD3, RI = 53.365% × (1-30.064%) = 0.373; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0098] Example 5
[0099] Donor No. 15: PBMCs from Donor No. 15 were stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 6 shown.
[0100] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 45.562%, while the proportion of CD45RA to CD3 is 59.682%, RI = 45.562% × 59.682% = 0.272; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 40.250%, RI = 45.562% × (1-40.250%) = 0.272; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0101] Example 6
[0102] Donor No. 16: PBMCs of Donor No. 16 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 7 shown.
[0103] The reconstruction index RI value is calculated as follows: CD3 accounts for 50.882% of the total cell number, while CD45RA accounts for 55.860% of CD3, RI = 50.882% × 55.860% = 0.284; or the CD45RO ratio is calculated, CD45RO accounts for 44.065% of CD3, RI = 50.882% × (1-44.065%) = 0.285. The RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0104] Example 7
[0105] Donor No. 17: PBMCs of Donor No. 17 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Figure 8 shown.
[0106] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 68.044%, while the proportion of CD45RA to CD3 is 46.268%, RI = 68.044% × 46.268% = 0.315, or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 53.656%, RI = 68.044% × (1-53.656%) = 0.315; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0107] Example 8
[0108] Donor No. 18: PBMCs of Donor No. 18 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig. 9 shown.
[0109] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 44.210%, while the proportion of CD45RA to CD3 is 54.493%, RI = 44.210% × 54.493% = 0.241; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 45.453%, RI = 44.210% × (1-45.453%) = 0.241; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0110] Example 9
[0111] Donor No. 19: PBMCs of Donor No. 19 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.10 shown.
[0112] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 47.431%, while the proportion of CD45RA to CD3 is 29.061%, RI = 47.431% × 29.061% = 0.138, or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 70.879%, RI = 47.431% × (1-70.879%) = 0.138; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0113] Example 10
[0114] Donor No. 2: PBMCs of Donor No. 2 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.11 shown.
[0115] The reconstruction index RI value is calculated as follows: CD3 accounts for 70.611% of the total cell number, while CD45RA accounts for 65.76% of CD3, RI = 70.611% × 65.753% = 0.464; or the CD45RO ratio is calculated, CD45RO accounts for 34.237% of CD3, RI = 70.611% × (1-34.237%) = 0.464; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0116] Embodiment 11
[0117] Donor No. 3: PBMCs of Donor No. 3 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.12 shown.
[0118] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 58.874%, while the proportion of CD45RA to CD3 is 64.207%, RI = 58.874% × 64.207% = 0.378; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 35.778%, RI = 58.874% × (1-35.778%) = 0.378, the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0119] Example 12
[0120] Donor No. 34: PBMCs of Donor No. 34 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.13 shown.
[0121] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 13.702%, while the proportion of CD45RA to CD3 is 53.492%, RI = 13.702% × 53.492% = 0.073; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 46.274%, RI = 13.702% × (1-46.274%) = 0.074; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0122] Embodiment 13
[0123] Donor No. 101: PBMCs of Donor No. 101 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.14 shown.
[0124] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 42.708%, while the proportion of CD45RA to CD3 is 59.561%, RI = 42.708% × 59.561% = 0.254; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 40.329%, RI = 42.708% × (1-40.329%) = 0.255; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0125] Embodiment 14
[0126] Donor No. 102: PBMCs of Donor No. 102 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.15 shown.
[0127] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 64.252%, while the proportion of CD45RA to CD3 is 48.694%, RI = 64.252% × 48.694% = 0.313; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 51.137%, RI = 64.252% × (1-51.137%) = 0.314, the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0128] Embodiment 15
[0129] Donor No. 103: PBMCs of Donor No. 103 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.16 shown.
[0130] The reconstruction index RI value is calculated as follows: CD3 accounts for 53.361% of the total cell number, while CD45RA accounts for 71.512% of CD3, RI = 53.361% × 71.512% = 0.382; or the CD45RO ratio is calculated, CD45RO accounts for 28.471% of CD3, RI = 53.361% × (1-28.471%) = 0.382; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0131] Example 16
[0132] Donor No. 104: PBMCs of Donor No. 104 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.17 shown.
[0133] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 44.720%, while the proportion of CD45RA to CD3 is 53.238%, RI = 44.720% × 53.238% = 0.238; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 46.670%, RI = 44.720% × (1-46.670%) = 0.238; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0134] Embodiment 17
[0135] Donor No. 105: PBMCs of Donor No. 105 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.18 shown.
[0136] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 68.377%, while the proportion of CD45RA to CD3 is 60.064%, RI = 68.377% × 60.064% = 0.410; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 39.819%, RI = 68.377% × (1-39.819%) = 0.411; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0137] Embodiment 18
[0138] Donor No. 4093: PBMCs of Donor No. 4093 were obtained, stained with fluorescent antibodies and analyzed by flow cytometry. The results are as follows: Fig.19 shown.
[0139] The reconstruction index RI value is calculated as follows: the proportion of CD3 to the total cell number is 26.029%, while the proportion of CD45RA to CD3 is 58.490%, RI = 26.029% × 58.490% = 0.152; or the CD45RO proportion is calculated, the proportion of CD45RO to CD3 is 40.968%, RI = 26.029% × (1-40.968%) = 0.152; the RI calculated using CD45RO and CD45RA are the same in percentile decimal points, and the relative error is less than 1%.
[0140] Example 19 Donor (PBMC) animal immune system reconstruction
[0141] Take 6 to 8 weeks of NSG from JAXSON Lab in the United States TM Mice or mice with severe T / B / NK cell deficiency of the same level were fed adaptively for one week, weighed and inoculated with the PBMCs of Examples 1 to 18, respectively. The inoculation information is shown in Table 3 below.
[0142] Table 3 PBMC inoculation information after resuscitation
[0143] Animal strains PBMC Number of animals Vaccination method Inoculated cell amount / cell Inoculated cell suspension volume / cell NSG Donor 5 Tail vein iv <![CDATA[5×10 6 ]]> 0.1mL
[0144] The proportion of human CD45+ (i.e., hCD45+) cells in the mouse blood was measured 7 days before and after the inoculation of PBMC cells. The peripheral blood immune system reconstruction values were tested once a week after the first test. The test scheme is shown in Table 4 below.
[0145] Table 4 Flow cytometry detection of peripheral blood PBMC reconstitution
[0146] Detection indicators Analytical methods hCD45, mCD45 <![CDATA[Peripheral blood human PBMC reconstruction ratio (%) = hCD45 + / (hCD45 + mCD45) × 100%]]>
[0147] Record the reconstruction values of Donor (PBMC) of each embodiment, the results are as follows Fig. 20 and Fig.21 shown.
[0148] Example 20 Determination of Cut-off Value
[0149] The RI of each donor was calculated, and combined with the reconstruction ratio of about 19 to 21 days in vivo (see Table 5), linear regression statistics were performed, and the reconstruction ratio value greater than 20% commonly used in the industry was used as the limit for determining successful immune reconstruction. The intersection of the two was used as the setting point of the cut-off value, such as Fig. 22 As shown. By calculation, the RI value corresponding to the intersection point is about 0.2. At this time, there are 2 cases with RI greater than 0.2 and reconstruction ratio less than 20%, and 13 cases with RI greater than 0.2 and reconstruction ratio higher than 20%. According to RI>0.2, the positive ratio is 13 / 15=86.6%, and all samples with RI≤0.2 are negative. If this reconstruction index is not used for screening, the success rate is 13 / 18=72.2%. Therefore, RI is set at 0.2, which is a suitable in vitro screening standard, which can completely exclude donors with poor reconstruction and improve the success rate of donor reconstruction screening.
[0150] Table 5 Human CD45 reconstitution ratio of Donor reconstitution in mice around 19 to 21 days
[0151]
[0152]
[0153] Embodiment 21
[0154] Human PBMC donors are basically CD45 positive, so the cells circled by the CD45 marker are equivalent to the total cells when the cut-off is set. According to the COA (Product Analysis Report) provided by the donor supplier, we picked a batch of donors that need to be modeled in mice, the ratio of CD3 of CD45 and the ratio of CD45RA of CD3, calculated their RI, and determined their in vivo reconstruction ability based on the cut-off set to 0.2. Figures 23-34 For specific examples.
[0155] Each of the 12 donors was injected with 5×10E6 cells through the tail vein. After 20 days, the reconstitution ratio of human CD45 to the total human CD45+mouse CD45 was measured (see Table 6). The correlation between the reconstitution index RI and the reconstitution ratio was analyzed based on the reconstitution index RI calculated according to the donor manufacturer's COA report. Fig.35 As shown in the figure, the correlation when the cut-off is determined is almost perfectly reproduced. RI = 0.2 filters out poorly reconstructed donors. Among the 8 donors with RI> 0.2, 7 can be well reconstructed, with a success rate of 7 / 8 = 87.5%. If this reconstruction index is not used for screening, the success rate is 7 / 12 = 58.3%. In comparison, the reconstruction success rate can be significantly improved.
[0156] Table 6 Human CD45 reconstitution ratio in a new batch of mice after Donor reconstitution for about 19 to 21 days
[0157] Donor Number Reconstruction Index, RI Reconstruction ratio, RP 9044# 39.95%×(23.781%+22.118%)=0.183 16.834 8006A# 54.727%×(23.436%+28.871%)=0.286 33.219 4071# 58.104%×(40.323%+12.718%)=0.308 41.542 0903C# 44.746%×(37.28%+14.24%)=0.231 24.591 0503C# 62.162%×(33.61%+27.42%)=0.379 39.152 0027# 38.729%×(39.437%+20.928%)=0.234 12.221 3070# 51.678%×(35.687%+15.505%)=0.265 40.887 7023# 26.964%×(37.616%+5.746%)=0.117 10.583 2066# 52.295%×(40.674%+16.086%)=0.297 29.116 4089# 35.302%×(27.836%+12.770%)=0.143 9.546 2101# 38.960%×(26.960%+8.397%)=0.138 15.715 9113# 57.689%×(24.977%+22.388%)=0.273 22.485
[0158] In summary, the Reconstitution Index (RI) can be used to more accurately quantify the immune system reconstruction ability of PBMC, and the use of the cut-off setting of RI = 0.2 can well screen out poorly reconstructed donors, so that well-reconstructed donors can be quickly selected, which greatly speeds up the construction process of the humanized immune system mouse model in the tumor immune drug efficacy screening process, and significantly improves the success rate of the construction of the humanized immune system mouse model. The detection method of the present invention is helpful for the selection of donors and experimental time planning, while also reducing costs, and can quickly and well promote the establishment of humanized experimental animal models used in drug research and development, and contribute to the development of new anti-tumor immune-related drugs, and has good application value.
[0159] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0160] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A method for detecting the immune system reconstruction ability of PBMC, characterized in that: The following steps are involved: Obtain PBMC samples; Obtaining a ratio a of CD3-positive cells in the PBMC sample and b ratio of CD45RA-positive cells in the CD3-positive cells, and calculating the ratio of CD45RA-positive cells in the PBMC sample by a×b as a reconstruction index; The larger the reconstruction index value, the higher the immune system reconstruction ability of the PBMC sample, and the cut-off value of the reconstruction index is 0.2; The reconstruction ability is the reconstruction ability reflected in the humanized mouse model of the immune system; the mice used in the model are T / B / NK cell combined deficiency mice.
2. The detection method according to claim 1, characterized in that: The method for obtaining the proportion of CD45RA-positive cells in the CD3-positive cells comprises the following steps: obtaining the proportion c of CD45RO-positive cells in the CD3-positive cells, and obtaining the proportion of CD45RA-positive cells in the CD3-positive cells by calculating 1-c.
3. The detection method according to claim 1, characterized in that: The PBMC sample is a human PBMC sample, and the method for obtaining the proportion of CD3 positive cells in the PBMC sample comprises the following steps: obtaining the number d of CD45 positive cells and the number e of CD3 positive cells in the PBMC sample, and calculating the proportion of CD3 positive cells in the PBMC sample according to e / d.
4. The detection method according to claim 1, characterized in that: The proportion of CD45RA-positive cells in the PBMC samples was detected by flow cytometry.
5. The detection method according to claim 4, characterized in that: The flow cytometry includes the following steps: taking PBMC samples into a flow tube, staining with fluorescent antibodies, and then placing them in a flow cytometer for detection and analysis.
6. The detection method according to claim 5, characterized in that: The method for staining with fluorescent antibodies comprises the following steps: mixing the PBMC sample with the fluorescent antibody, incubating at room temperature in the dark for 10 to 30 minutes, adding a buffer solution, centrifuging at 100 g to 400 g for 1 to 5 minutes to obtain a precipitate, and then adding a buffer solution to resuspend.
7. A method for screening drugs for treating immunodeficiency diseases, characterized in that: The following steps are involved: Detecting the immune system reconstruction ability of PBMC according to the detection method according to any one of claims 1 to 6; PBMCs with a reconstruction index > 0.2 were selected and inoculated into experimental animals to construct experimental animal models; Candidate drugs are tested using the experimental animal model.
8. A computer-readable storage medium, characterized in that: The computer storage medium is used to store computer instructions, programs, code sets or instruction sets, which, when run on a computer, enable the computer to execute the detection method according to any one of claims 1 to 6.
9. An electronic device, characterized in that: include: one or more processors; as well as A computer-readable storage medium, wherein the computer storage medium is used to store computer instructions, programs, code sets or instruction sets, and when the computer-readable storage medium is run on a computer, the one or more processors implement the detection method according to any one of claims 1 to 6.
Citation Information
Patent Citations
Application of ligand-mediated dendritic cell targeting Texosomes bionic body as tumor vaccine
CN104906567A
Kit for detecting existence of leukemia stem cells
CN105087762A
Screening method and application of T cells with high anticancer activity
CN108795858A
Immunodeficient mouse
CN111372449A
Construction method of humanized immune system mouse with NK cell and ADCC capacity
CN111485001A
